In a patient with heart failure with reduced ejection fraction and ischemic cardiomyopathy, diabetes (A1c 7.2%) on insulin, glipizide, empagliflozin, and metformin, and hyperlipidemia on atorvastatin and fenofibrate, who has mildly elevated AST (43 U/L) and ALT (63 U/L) without any medication changes, should I hold atorvastatin and metformin and recheck liver enzymes?

Do Not Hold Atorvastatin or Metformin - Hold Fenofibrate Instead

In this patient with mildly elevated transaminases (AST 43, ALT 63), you should discontinue fenofibrate and continue both atorvastatin and metformin. The fenofibrate is the most likely culprit for hepatotoxicity and should be stopped immediately, while the other medications provide critical cardiovascular and glycemic benefits that outweigh minimal hepatic risk at these enzyme levels.

Rationale for Stopping Fenofibrate

Fenofibrate carries significant hepatotoxicity risk and should be discontinued when ALT/AST exceed 3x upper limit of normal or with any concerning liver injury signs 1. While your patient's transaminases are only mildly elevated (approximately 1.5x normal), the FDA labeling explicitly warns that:

• Serious drug-induced liver injury (DILI) including liver transplantation and death have been reported with fenofibrate
• DILI can occur within weeks or after months of therapy
• Fenofibrate is contraindicated in patients with unexplained persistent liver function abnormalities
• The drug should be discontinued if elevated enzyme levels persist 1

The combination of fenofibrate with atorvastatin significantly increases myopathy risk and provides questionable additional cardiovascular benefit 2. The AHA scientific statement notes that fibrate-statin combinations should be avoided unless benefits clearly outweigh risks 2.

Why Continue Atorvastatin

Atorvastatin should be continued because:

• These transaminase elevations (1.5x normal) are mild and commonly seen with statins without clinical significance
• Atorvastatin has minimal renal excretion (<2%) making it safer in this patient with diabetes and likely some renal impairment 2
• In ischemic cardiomyopathy and HFrEF, statin therapy reduces mortality and cardiovascular events - discontinuing would increase morbidity/mortality risk
• The threshold for statin discontinuation is ALT/AST >3x upper limit of normal, not the mild elevations seen here 2

Why Continue Metformin

Metformin must be continued in this patient with stable heart failure 3. The 2025 ADA guidelines explicitly state:

• FDA restrictions on metformin use in heart failure were removed in 2006
• Observational studies show metformin users with diabetes and heart failure have better outcomes than those on other antihyperglycemic agents
• Metformin may be used safely in stable heart failure as long as kidney function remains adequate 3

Metformin does not cause clinically significant hepatotoxicity. The mild transaminase elevations are far more consistent with fenofibrate effect. Research confirms metformin can be used safely in stable HF patients 4, 5.

The Empagliflozin (Jardiance) Advantage

Your patient is already on empagliflozin, which is critical to continue as SGLT2 inhibitors:

• Reduce heart failure hospitalizations by 27-35% in HFrEF 3
• Improve cardiovascular outcomes regardless of diabetes status 6
• Are now considered backbone therapy for HFrEF 7

Specific Action Plan

1. Discontinue fenofibrate immediately - it provides minimal additional benefit over statin monotherapy and carries the highest hepatotoxicity risk
2. Continue atorvastatin - essential for secondary prevention in ischemic cardiomyopathy
3. Continue metformin - safe and beneficial in stable HFrEF with adequate renal function
4. Recheck LFTs in 4-6 weeks after stopping fenofibrate
5. Monitor for symptoms of liver injury (jaundice, dark urine, abdominal pain, malaise) 1
6. Check CPK if any muscle symptoms develop, as statin-fibrate combinations increase myopathy risk 2, 1

Common Pitfall to Avoid

Do not reflexively stop statins and metformin for mild transaminase elevations. This knee-jerk reaction removes medications with proven mortality benefit in HFrEF and ischemic heart disease. The fenofibrate is the expendable agent here - it adds marginal lipid benefit while substantially increasing toxicity risk when combined with a statin 2.

If LFTs fail to improve after stopping fenofibrate, then consider other causes (fatty liver disease is common with diabetes, obesity, and metabolic syndrome). Only discontinue atorvastatin if ALT/AST rise above 3x normal or if accompanied by bilirubin elevation 1.